Search results
Showing 406 to 420 of 436 results for cardiovascular disease
Percutaneous mitral valve leaflet repair for mitral regurgitation (IPG649)
Evidence-based recommendations on percutaneous mitral valve leaflet repair for mitral regurgitation in adults. This involves attaching a clip to the leaflets of the mitral valve.
View recommendations for IPG649Show all sections
Evidence summaries: new medicines – Integrated process statement (PMG11)
This integrated process statement has been produced to explain how 'Evidence summaries: new medicines' (ESNMs) are developed. It provides an overview of the key process principles and describes all stages of the development of ESNMs
Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease. This involves implanting electrodes into the diaphragm to make it contract. This gradually strengthens the diaphragm and may eventually help the person to breathe without a ventilator.
Percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices (IPG380)
Evidence-based recommendations on percutaneous atherectomy of femoropopliteal arterial lesions with plaque excision devices. This involves using a special cutting device to remove excess debris inside diseased blood vessels.
View recommendations for IPG380Show all sections
Sections for IPG380
Evidence-based recommendations on baricitinib (Olumiant) for treating severe alopecia areata in adults.
Zanubrutinib for treating chronic lymphocytic leukaemia (TA931)
Evidence-based recommendations on zanubrutinib (Brukinsa) for treating chronic lymphocytic leukaemia in adults.
NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .
LATITUDE NXT Patient Management System for monitoring cardiac devices at home (MIB67)
NICE has developed a medtech innovation briefing (MIB) on the LATITUDE NXT Patient Management System for monitoring cardiac devices at home
CareLink network service for remote monitoring of people with cardiac devices (MIB64)
NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Preparing for the next breakthroughs in liver disease treatments
With no licensed treatments for MASH, a serious liver condition affecting 3 million in the UK, NICE has co-developed a framework with patients, clinicians, and industry to accelerate access to promising new medicines.